

List of Progress in Hematology "Review Series" 2020-2021

*****2021*****

Advances in diagnosis and treatment of disseminated intravascular coagulation (Edited by Hidesaku Asakura)

1. Asakura H. Diversity of disseminated intravascular coagulation and selection of appropriate treatments. Int J Hematol. 2021;113:10-4.
2. Yamada S, Asakura H. International Journal of Hematology Management of disseminated intravascular coagulation associated with aortic aneurysm and vascular malformations. Int J Hematol. 2021;113:15-23.
3. Iba T, Connors JM, Nagaoka I, Levy JH. Recent advances in the research and management of sepsis-associated DIC. Int J Hematol. 2021;113:24-33
4. Ikezoe T. Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies. Int J Hematol. 2021;113:34-44.
5. Asakura H, Ogawa H. COVID-19-associated coagulopathy and disseminated intravascular coagulation. Int J Hematol. 2021;113:45-57.

Aiming for the final goal (Edited by Shinya Kimura)

1. Kimura S. Evolution of CML treatment. Int J Hematol. 2021; 113:622-3.
2. Morita K, Sasaki K. Current status and novel strategy of CML. Int J Hematol. 2021; 113:624-31.

3. Lee H, Basso IN, Kim DDH. Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia. *Int J Hematol.* 2021; 113:632-41.
4. Ureshino H. Treatment-free remission and immunity in chronic myeloid leukemia. *Int J Hematol.* 2021; 113:642-7.
5. Naka K. New routes to eradicating chronic myelogenous leukemia stem cells by targeting metabolism. *Int J Hematol.* 2021; 113:648-55.

CAR-T cell therapy, Now the time for the next ! (Edited by Hiroshi Fujiwara)

1. Fujiwara H. Efforts to maximize the potential of CAR-T therapy for cancer, from T-bodies to CAR-immune cells. *Int J Hematol.* 2021; in press.
<https://link.springer.com/article/10.1007/s12185-021-03213-8>
2. Lundh S, Maji S, Melenhorst JJ. Next-generation CAR T cells to overcome current drawbacks. *Int J Hematol.* 2021; in press.
<https://link.springer.com/article/10.1007/s12185-020-02923-9>
3. Wang X, Diamond DJ, Forman SJ, Nakamura R. Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine. *Int J Hematol.* 2021; in press.
<https://link.springer.com/article/10.1007/s12185-021-03215-6>
4. Biederstädt A, Rezvani K. Engineering the next generation of CAR-NK immunotherapies. *Int J Hematol.* 2021; in press.
<https://link.springer.com/article/10.1007/s12185-021-03209-4>

5. Ueda T, Kaneko S. International Journal of Hemat Induced pluripotent stem cell-derived natural killer cells gene-modified to express chimeric antigen receptor-targeting solid tumors. Int J Hematol. 2021; in press.
<https://link.springer.com/article/10.1007/s12185-020-02951-5>

2020

Current progress and future direction in the treatment for haemophilia (Edited by Midori Shima)

1. Kitazawa T, Shima M. Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity. Int J Hematol. 2020; 111:20–30.
<https://link.springer.com/article/10.1007/s12185-018-2545-9>
2. Ohmori T. Advances in gene therapy for hemophilia: basis, current status, and future perspectives. Int J Hematol. 2020; 111:31–41.
<https://link.springer.com/article/10.1007/s12185-018-2545-9>
3. Chowdary P. Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia. Int J Hematol. 2020; 111:42–50.
<https://link.springer.com/article/10.1007/s12185-018-2548-6>

Progress in elucidation of molecular pathophysiology and its application to therapeutic decisions of MPNs (Edited by Katsuto Takenaka)

1. Jia R, Kralovics R. Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions. Int J Hematol. 2020; 111:182–91.
<https://link.springer.com/article/10.1007/s12185-019-02778-9>
2. Bose P, Verstovsek S. Mutational profiling in myelofibrosis: implications for management. Int J Hematol. 2020; 111:192–9.

- <https://link.springer.com/article/10.1007/s12185-019-02758-z>
3. Araki M, Komatsu N. The role of calreticulin mutations in myeloproliferative neoplasms. *Int J Hematol.* 2020; 111:200-5.
<https://link.springer.com/article/10.1007/s12185-019-02800-0>
 4. Shide K. The role of driver mutations in myeloproliferative neoplasms: insights from mouse models. *Int J Hematol.* 2020; 111:206-16.
<https://link.springer.com/article/10.1007/s12185-019-02803-x>

Recent Advances in Biology and Treatment of Multiple Myeloma (Edited by Hirokazu Tanaka)

1. Kikuchi J. Molecular basis of clonal evolution in multiple myeloma. *Int J Hematol.* 2020; 111:496–511.
<https://link.springer.com/article/10.1007/s12185-020-02829-6>
2. Suzuki K. Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost. *Int J Hematol.* 2020; 111:512-8.
<https://link.springer.com/article/10.1007/s12185-020-02841-w>
3. Takamatsu H. Clinical value of measurable residual disease testing for multiple myeloma and implementation in Japan. *Int J Hematol.* 2020; 111:519-29.
<https://link.springer.com/article/10.1007/s12185-020-02828-7>
4. Hosen N. Chimeric antigen receptor T-cell therapy for multiple myeloma. *Int J Hematol.* 2020; 111:530-4.
<https://link.springer.com/article/10.1007/s12185-020-02827-8>

B1cells: their ontogeny and malignant counterpart (Edited by Naoyuki Katayama)

1. Yoshimoto M. The ontogeny of murine B-1a cells. *Int J Hematol.* 2020; 111:622-7.
<https://link.springer.com/article/10.1007/s12185-019-02787-8>
2. Kageyama Y, Katayama N. Ontogeny of human B1 cells. *Int J Hematol.* 2020; 111:628-33.

<https://link.springer.com/article/10.1007/s12185-019-02775-y>

3. Kikushige Y. Pathophysiology of chronic lymphocytic leukemia and human B1 cell development. *Int J Hematol.* 2020; 111:634-41.

<https://link.springer.com/article/10.1007/s12185-019-02788-7>

4. Suzumiya J, Takizawa J. Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal? *Int J Hematol.* 2020; 111:642-56.

<https://link.springer.com/article/10.1007/s12185-020-02867-0>